Join to view full profile
222 E 41st StFl 13New York, NY 10017
Phone+1 212-263-4838
Dr. Feigin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Rochester Medical CenterResidency, Neurology, 1989 - 1992
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1988 - 1989
Columbia University Vagelos College of Physicians and SurgeonsClass of 1988
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 1992 - 2027
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Complete), Allscripts, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2014, 2016-2017
Clinical Trials
- Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
Publications & Presentations
PubMed
- Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.Horacio Kaufmann, Jose-Alberto Palma, Patricio Millar Vernetti, Mechteld Kuijpers, Grace Nkrumah
Clinical Autonomic Research. 2026-04-01 - Drug Development.Elizabeth E Evans, Terrence L Fisher Jr, Vikas Mishra, Leslie Balch, Elaine E Gersz
Alzheimer's & Dementia. 2025-12-01 - 5 citationsPridopidine in early-stage manifest Huntington's disease: a phase 3 trial.Ralf Reilmann, Andrew Feigin, Anne E Rosser, Sandra K Kostyk, Carsten Saft
Nature Medicine. 2025-11-01
Press Mentions
AAN 2023: Pridopidine Phase 3 Trial Misses Goal, but Benefits Seen for SomeMay 2nd, 2023- Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington's Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual MeetingApril 25th, 2023
- Parkinson’s Cases May Be 50% Higher Than Previously Thought: Why That’s Important to KnowDecember 15th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
